دورية أكاديمية
أعرض في EDS

Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
المؤلفون: Kurago Z; Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia at Augusta University, Medical College of Georgia, Augusta University, Augusta, GA, United States., Guo G; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, United States.; Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, United States., Shi H; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, United States.; Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, United States., Bollag RJ; Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, United States.; Department of Pathology, Medical College of Georgia, Augusta University, Augusta, GA, United States., Groves MW; Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, United States.; Department of Otolaryngology, Medical College of Georgia, Augusta University, Augusta, GA, United States., Byrd JK; Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, United States.; Department of Otolaryngology, Medical College of Georgia, Augusta University, Augusta, GA, United States., Cui Y; Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, United States.; Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA, United States.
المصدر: Frontiers in immunology [Front Immunol] 2023 Jun 26; Vol. 14, pp. 1212209. Date of Electronic Publication: 2023 Jun 26 (Print Publication: 2023).
نوع المنشور: Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Anti-Infective Agents* , Pulmonary Surfactants* , Neoplasms*/drug therapy, Humans ; B7-H1 Antigen ; CTLA-4 Antigen ; Programmed Cell Death 1 Receptor ; Penicillins ; Immunotherapy ; Fibrinolytic Agents ; Anesthetics, Local ; Tumor Microenvironment
مستخلص: The cell surface enzyme CD73 is increasingly appreciated as a pivotal non-redundant immune checkpoint (IC) in addition to PD-1/PD-L1 and CTLA-4. CD73 produces extracellular adenosine (eADO), which not only inhibits antitumor T cell activity via the adenosine receptor (AR) A 2A R, but also enhances the immune inhibitory function of cancer-associated fibroblasts and myeloid cells via A 2B R. Preclinical studies show that inhibition of the CD73-adenosinergic pathway in experimental models of many solid tumors either as a monotherapy or, more effectively, in combination with PD-1/PD-L1 or CTLA-4 IC blockades, improves antitumor immunity and tumor control. Consequently, approximately 50 ongoing phase I/II clinical trials targeting the CD73-adenosinergic IC are currently listed on https://clinicaltrials.gov. Most of the listed trials employ CD73 inhibitors or anti-CD73 antibodies alone, in combination with A 2A R antagonists, and/or with PD-1/PD-L1 blockade. Recent evidence suggests that the distribution of CD73, A 2A R and A 2B R in tumor microenvironments (TME) is heterogeneous, and this distribution affects CD73-adenosinergic IC function. The new insights have implications for the optimally effective, carefully tailored approaches to therapeutic targeting of this essential IC. In the mini-review, we briefly discuss the cellular and molecular mechanisms of CD73/eADO-mediated immunosuppression during tumor progression and therapy in the spatial context of the TME. We include preclinical data regarding therapeutic CD73-eADO blockade in tumor models as well as available clinical data from completed trials that targeted CD73-adenosinergic IC with or without PD-1/PD-L1 inhibitors and discuss factors that are potentially important for optimal therapeutic outcomes in cancer patients.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2023 Kurago, Guo, Shi, Bollag, Groves, Byrd and Cui.)
References: Blood. 2008 Sep 1;112(5):1822-31. (PMID: 18559975)
Int J Mol Sci. 2019 Nov 14;20(22):. (PMID: 31739402)
Nat Rev Cancer. 2017 Nov 22;17(12):765. (PMID: 29162946)
Cancer Res. 2018 Feb 15;78(4):1003-1016. (PMID: 29229601)
Int Immunopharmacol. 2021 Jul;96:107645. (PMID: 33894488)
Front Immunol. 2019 Feb 07;10:162. (PMID: 30792717)
Nat Rev Cancer. 2020 Apr;20(4):203-217. (PMID: 32161398)
Cancer Immunol Res. 2020 Apr;8(4):465-478. (PMID: 32047024)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
J Immunol. 2009 Apr 15;182(8):4616-23. (PMID: 19342636)
Clin Cancer Res. 2022 Nov 14;28(22):4871-4884. (PMID: 36044531)
JCI Insight. 2020 Sep 3;5(17):. (PMID: 32721947)
Cancer Res. 2014 Dec 15;74(24):7239-49. (PMID: 25341542)
J Neurosci. 2019 May 29;39(22):4387-4402. (PMID: 30926752)
J Transl Med. 2017 Dec 4;15(1):244. (PMID: 29202855)
Trends Cancer. 2016 Feb 1;2(2):95-109. (PMID: 27014745)
Immunotherapy. 2019 Aug;11(11):983-997. (PMID: 31223045)
Cancer Immunol Res. 2018 Oct;6(10):1136-1149. (PMID: 30131376)
Front Immunol. 2021 May 19;12:699069. (PMID: 34093597)
Clin Cancer Res. 2013 Oct 15;19(20):5626-35. (PMID: 23983257)
Neoplasia. 2013 Dec;15(12):1400-9. (PMID: 24403862)
Cancer Immunol Immunother. 2021 Jul;70(7):1965-1976. (PMID: 33416944)
FASEB J. 2012 Jan;26(1):376-86. (PMID: 21926236)
Trends Cell Biol. 2021 Oct;31(10):829-842. (PMID: 34116887)
J Immunol. 2014 Sep 15;193(6):3155-64. (PMID: 25127858)
Drug Discov Today. 2017 Nov;22(11):1686-1696. (PMID: 28676406)
Nat Rev Immunol. 2015 Nov;15(11):669-82. (PMID: 26471778)
Nat Commun. 2020 Jan 24;11(1):515. (PMID: 31980601)
Cancer Immunol Res. 2020 Aug;8(8):1064-1074. (PMID: 32381524)
J Immunother Cancer. 2023 Feb;11(2):. (PMID: 36746510)
Nat Rev Immunol. 2016 Mar;16(3):177-92. (PMID: 26922909)
Int Immunopharmacol. 2023 Jan;114:109567. (PMID: 36529024)
Nat Commun. 2018 Aug 24;9(1):3437. (PMID: 30143634)
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14711-6. (PMID: 23964122)
J Immunol. 2005 Dec 15;175(12):8260-70. (PMID: 16339566)
Nature. 2018 Feb 22;554(7693):538-543. (PMID: 29443964)
Cancer Immunol Immunother. 2018 Aug;67(8):1271-1284. (PMID: 29923026)
J Immunol. 1999 Mar 15;162(6):3607-14. (PMID: 10092821)
J Clin Invest. 2020 Mar 2;130(3):1185-1198. (PMID: 31770109)
Cancer Cell. 2016 Sep 12;30(3):391-403. (PMID: 27622332)
J Thorac Oncol. 2023 May;18(5):650-656. (PMID: 36641093)
Neoplasia. 2017 Jul;19(7):530-536. (PMID: 28582704)
J Clin Invest. 2022 Jul 15;132(14):. (PMID: 35671108)
J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33361405)
Cancer Discov. 2020 Jan;10(1):40-53. (PMID: 31732494)
Immunotherapy. 2014;6(1):19-21. (PMID: 24341879)
Nat Rev Cancer. 2018 Oct;18(10):601-618. (PMID: 30006588)
Cancer Res. 2014 Dec 15;74(24):7250-9. (PMID: 25377469)
Annu Rev Immunol. 2019 Apr 26;37:325-347. (PMID: 30676821)
Cell Rep. 2022 Aug 2;40(5):111150. (PMID: 35926464)
J Exp Med. 2003 Sep 1;198(5):783-96. (PMID: 12939345)
Cancer Cell. 2019 Dec 9;36(6):582-596. (PMID: 31821783)
Trends Pharmacol Sci. 2016 Jun;37(6):419-434. (PMID: 26944097)
Clin Cancer Res. 2020 May 1;26(9):2176-2187. (PMID: 31953314)
Clin Cancer Res. 2016 Jan 1;22(1):158-66. (PMID: 26253870)
Nat Rev Cancer. 2017 Dec;17(12):709-724. (PMID: 29059149)
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629. (PMID: 32514148)
Oncoimmunology. 2020 Apr 23;9(1):1746138. (PMID: 32363113)
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44. (PMID: 23483055)
Nat Rev Cancer. 2013 Dec;13(12):842-57. (PMID: 24226193)
J Immunol. 2011 Dec 1;187(11):6120-9. (PMID: 22039302)
Annu Rev Med. 2021 Jan 27;72:331-348. (PMID: 32903139)
Nat Rev Cancer. 2023 May;23(5):295-316. (PMID: 37046001)
J Surg Oncol. 2012 Dec;106(7):918-9; author reply 920. (PMID: 22585744)
Oncoimmunology. 2015 May 5;4(11):e1046675. (PMID: 26451321)
Trends Immunol. 2009 Jun;30(6):263-70. (PMID: 19427267)
Cancer Immunol Immunother. 2012 Jun;61(6):917-26. (PMID: 22116345)
Cancer Res. 2016 Aug 1;76(15):4372-82. (PMID: 27221704)
Nat Commun. 2021 May 28;12(1):3236. (PMID: 34050151)
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7. (PMID: 16916931)
Nat Rev Drug Discov. 2006 Mar;5(3):247-64. (PMID: 16518376)
Oncotarget. 2016 Sep 20;7(38):61690-61702. (PMID: 27557512)
Nat Med. 2020 Jan;26(1):39-46. (PMID: 31873309)
Physiol Rev. 2018 Jul 1;98(3):1591-1625. (PMID: 29848236)
Ann Oncol. 2018 Apr 1;29(4):1056-1062. (PMID: 29145561)
Nat Commun. 2019 Jan 11;10(1):150. (PMID: 30635578)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Nat Commun. 2021 Nov 18;12(1):6726. (PMID: 34795254)
Cancer Res. 2015 Nov 1;75(21):4494-503. (PMID: 26363007)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
Blood. 2008 Jan 1;111(1):251-9. (PMID: 17909080)
Oncotarget. 2016 Sep 27;7(39):64274-64288. (PMID: 27590504)
Purinergic Signal. 2006 Jun;2(2):351-60. (PMID: 18404475)
J Immunol. 2005 Jan 15;174(2):1073-80. (PMID: 15634932)
Int J Mol Sci. 2019 Oct 17;20(20):. (PMID: 31627281)
Trends Cancer. 2021 Aug;7(8):731-750. (PMID: 34074623)
Front Mol Biosci. 2019 Jul 24;6:60. (PMID: 31396523)
J Immunol. 2011 Feb 15;186(4):2444-53. (PMID: 21242513)
Curr Opin Pharmacol. 2016 Aug;29:90-6. (PMID: 27429212)
Immunol Rev. 2017 Mar;276(1):121-144. (PMID: 28258700)
Oncotarget. 2017 Jan 31;8(5):8738-8751. (PMID: 28060732)
معلومات مُعتمدة: R21 DE028716 United States DE NIDCR NIH HHS
فهرسة مساهمة: Keywords: A2AR; A2BR; CD39; CD73; NT5E; adenosine; combination therapy; immune checkpoint inhibitor
المشرفين على المادة: 0 (B7-H1 Antigen)
0 (CTLA-4 Antigen)
0 (Programmed Cell Death 1 Receptor)
0 (Penicillins)
0 (Anti-Infective Agents)
0 (Pulmonary Surfactants)
0 (Fibrinolytic Agents)
0 (Anesthetics, Local)
تواريخ الأحداث: Date Created: 20230712 Date Completed: 20230713 Latest Revision: 20230729
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10330720
DOI: 10.3389/fimmu.2023.1212209
PMID: 37435071
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2023.1212209